RCS - Intnl. Biotechnology - Latest Factsheet and Blog

International Biotechnology TrustAnnouncement

03/12/2024 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241203:nRSC6241Oa&default-theme=true

RNS Number : 6241O  Intl. Biotechnology Trust PLC  03 December 2024

INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")

 

Latest Factsheet and Blog

 

IBT's factsheet for the month ended 31 October 2024 is now available directly
via its web page. Please click here
(https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/international-biotechnology-trust/)
, then 'latest factsheet'.

 

Obesity has long been a significant global health challenge, particularly in
the western world, due to the implications it can have for associated
conditions such as heart disease, diabetes and certain cancers. Until
recently, treatments focused on lifestyle changes and pharmacological
interventions like appetite suppressants and fat absorption inhibitors.
However, these early drugs often had limited efficacy and significant side
effects, leading to a persistent demand for more effective solutions. Here, we
explore the continued innovation taking place in the obesity medication space.

The blog can be read here:

 

https://www.schroders.com/en-gb/uk/individual/content/the-future-of-obesity/
(https://www.schroders.com/en-gb/uk/individual/content/the-future-of-obesity/)

 

To sign up for IBT updates by email, please click here
(https://www.schroders.com/en-gb/uk/individual/never-miss-an-update/) .

 

 

ENDS

 

 

Enquiries:

 

 Schroder Investment Management Limited

 Kirsty Preston (PR)                                                     020 7658 6000

 Kerry Higgins (Company Secretary)                                       020 7658 6000

 Kaso Legg Communications (Financial PR)

                                                                         IBT@kl-communications.com (mailto:IBT@kl-communications.com)

 Charles Gorman

 Henry Taylor

 Effie Aye Maung Hider

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFXLFBZLLFFBQ